Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Micro-X Ltd. ( (AU:MX1) ).
Micro-X has completed the first full body CT laboratory test bench under its development agreement with U.S. government agency ARPA-H, triggering a A$1.6 million milestone payment. The engineering achievement follows a successful preliminary design review and marks a significant step in moving the project from early prototyping into full system development, reducing technical risk and advancing the program toward future clinical readiness.
The full body CT initiative now enters a critical design review and laboratory validation phase, where Micro-X will refine the system architecture and strengthen the platform. This progress underscores the company’s growing role in cutting-edge medical imaging and reinforces its strategic collaboration with U.S. government partners, with substantial development and validation work still ahead in the first phase of the contract this year.
The most recent analyst rating on (AU:MX1) stock is a Sell with a A$0.06 price target. To see the full list of analyst forecasts on Micro-X Ltd. stock, see the AU:MX1 Stock Forecast page.
More about Micro-X Ltd.
Micro-X Ltd is an Australian hi-tech company listed on the ASX that develops and commercialises X-ray products for global health and security markets using proprietary cold cathode carbon nanotube emitter technology. Its lightweight, low-power imaging systems support mobile radiology, next-generation airport security checkpoints, and advanced CT solutions, with development hubs in Adelaide and a growing presence in the U.S.
Average Trading Volume: 263,717
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$48.65M
For detailed information about MX1 stock, go to TipRanks’ Stock Analysis page.